CUTAQUIG (Immune Globulin Subcutaneous [Human] - hipp) is a 16.5% immune globulin solution for subcutaneous infusion (IGSC), indicated as replacement therapy for primary humoral immunodeficiency (PI) in adults and pediatric patients 2 years of age and older. This includes, but is not limited to, common variable immunodeficiency (CVID), X-linked agammaglobulinemia, congenital agammaglobulinemia , To this end, the efficacy and safety of SCIG 16.5% (Cutaquig®, Octapharma AG), at enhanced infusion regimens, was evaluated. SCIG 16.5% is currently approved for the treatment of PIDD in the US and Europe and for secondary immunodeficiencies in Europe and Canada [22 – 24]., What is Cutaquig? Cutaquig (for injection under the skin) is used to treat primary immunodeficiency diseases. Cutaquig is also used to treat chronic inflammatory demyelinating polyneuropathy (an autoimmune disorder in which the immune system attacks the nerves, causing muscle weakness and numbness)., This step-by-step guide will help you to administer cutaquig®subcutaneously. Cutaquig®contains immunoglobulin G (IgG), helping your immune system to fight off bacterial and viral infections. Cutaquig®is a medicine for people who are born with a reduced ability or inability to produce antibodies (primary immunodeficiency), or who are suffering from an acquired deficiency of antibodies , What Makes cutaquig Different? Cutaquig is a 16.5% immunoglobulin solution for subcutaneous infusion indicated for the treatment of PI in adult patients. The most significant difference between cutaquig and other SCIg products is its 16.5% concentration., See risks & benefits. Learn about CUTAQUIG® as an Rx option for adults & pediatric patients aged 2 years and older with primary immunodeficiency (PI) disease..